Dragonfly Therapeutics and Celgene Partnering on Blood-Cancer Therapies
Dragonfly Therapeutics and Celgene have teamed up to develop therapies for multiple myeloma and other blood cancers. The partners will use Dragonfly’s TriNKET immunotherapy…
News
First Patient Dosed in Phase 3 BOSTON Trial Evaluating Selinexor for Multiple Myeloma
Massachusetts–based Karyopharm Therapeutics announced that the first patient was dosed in its pivotal BOSTON Phase 3 clinical trial…
BMT Program at MedStar Georgetown Completes 100th Blood Stem Cell Transplant
John Theurer Cancer Center and MedStar Georgetown University Hospital have announced the completion of the 100th blood stem cell transplant since its joint…
Myeloma Patient Enrollment in 2 Keytruda Trials Suspended After Unexplained Deaths
Merck has suspended patient enrollment in two Phase 3 clinical trials, KEYNOTE-183 and KEYNOTE-185, testing Keytruda (pembrolizumab) in combination with other therapies in patients…
Caris Collaboration to Identify Eligible Participants for NCI-MATCH Trial
Caris Life Sciences is collaborating with the National Cancer Institute (NCI) to identify patients eligible to participate in the Phase 2 NCI-MATCH (Molecular Analysis for Therapy Choice) study,…
CAR T-Cell Therapy Nearly Eliminates Tumors in All Relapsed or Refractory Myeloma Patients in Phase 1 Trial
Updated results from an ongoing Phase 1 clinical study of bb2121, an investigational therapy for the treatment of multiple…
New CAR T-cell Therapy Seen to Induce Lasting Remission in Advanced Multiple Myeloma Patients
An ongoing Phase 1 trial testing a novel CAR T-cell therapy has shown promising results in relapsed or treatment-resistant (refractory) multiple myeloma patients. The new anti-BCMA…
Oncology Venture Enrolls First Multiple Myeloma Patient in Clinical Trial
Oncology Venture has enrolled the first patient into a Phase 1/2 trial of its compound APO010 in multiple myeloma. Patients in the study will…
Adding Darzalex to Standard Therapies in Multiple Myeloma Patients Continues to Show Improved Results
Adding Darzalex (daratumumab) to standard care therapies continues to show improved effectiveness in treating relapsed or refractory multiple myeloma, with no related toxicity, according to updated…
$4 Million Perelman Foundation Donation to Kick-start Myeloma Research Initiative
The first research program dedicated to the early detection and prevention of multiple myeloma will  be under way soon, thanks to a $4 million Perelman Family…
Recent Posts
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
- Tuspetinib as part of triple-combo therapy showing potential in AML